(Q38192690)

30 August 2017

1 reference

title

Predicting success: optimizing phase II ALS trials for the transition to phase III. (English)

1 reference

amyotrophic lateral sclerosis

30 August 2017

main subject

phase III clinical trial

0 references

phase II clinical trial

0 references

1 reference

2

Merit E Cudkowicz

1 reference

30 August 2017

James D Berry

1

1 reference

30 August 2017

Jeremy M Shefner

series ordinal

3

1 reference

30 August 2017

language of work or name

1 reference

1 March 2014

1 reference

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

1-2

1 reference

30 August 2017

page(s)

1-8

1 reference

Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Minocycline delays disease onset and mortality in a transgenic model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Minocycline in amyotrophic lateral sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

21 January 2018

The utility of futility.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Factors affecting the diagnostic delay in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Latent cluster analysis of ALS phenotypes identifies prognostically differing groups

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

A proposed staging system for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2013.838969

10.3109/21678421.2013.838969

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference